About us

At Humane Genomics, we use a first-principle approach to designing oncolytic viral therapies. With a dedicated team of experts and the guidance of world-class advisors, we are on a mission to revolutionize cancer treatment by leveraging the potential of RNA viruses to selectively target and eradicate cancer cells.

Why Our Viral Therapies Stand Out

We began by asking the question: What are the most important characteristics of an OVT? And then we designed our therapies to have these characteristics.

Unparalleled Safety. By employing both selective infection and selective replication, we ensure that our therapies target only cancer cells.
Highly Lytic. We use RNA viruses, which are highly lytic to ensure efficient killing of cancer cells.
Predictive Translation. We prioritize models that translate from in vitro to in vivo and ultimately to human applications.
Maximized Therapeutic Duration. By engineering low immunogenicity, therapies can persist without premature neutralization.
Systemic Delivery. Designed for systemic administration to improve odds of addressing present metastasis.
Cost-Effective Production. Highly replicative viruses can be potent and efficient to manufacture.

Our Cutting-Edge Platform

Engineering RNA viruses efficiently remains challenging, even with today’s technology. We pride ourselves on our state-of-the-art platform, developed to expedite the design and testing of our oncolytic viruses.

Here’s how it works:

Computer-Aided Design

Utilization of validated building blocks from our library and new ones from literature.
The freedom to design—changing base pairs or whole genes, tailored to specific needs.
Codon optimization to tune replication speed as needed.
Optimization for synthesis, followed by assembly using synthetic DNA.

DNA Synthesis

Sequence-perfect DNA, paving the way for a high-quality pipeline.
Rapid improvements enabling longer fragments, larger quantities, and reduced cost.

Making the genome and rescuing the virus

Assemble synthesized fragments to form the complete viral genome.
Cells are transfected, leading to virus production and efficacy testing. (Read more)

The Power of Vesicular Stomatitis Virus

Our therapies are based on Vesicular Stomatitis Virus (VSV) due to its advantages:

Ease of retargeting by changing the glycoprotein.
Highly lytic nature for fast and effective killing of cancer cells.
Linear genome simplifies engineering.
Well-researched with extensive published work.
Low seroprevalence helps reduce premature neutralization risk.

Our publications

For reference, here is a list of our publications in chronological order.